Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.

E, Araki; S, Yamashita; H, Arai; K, Yokote; J, Satoh; T, Inoguchi; J, Nakamura; H, Maegawa; N, Yoshioka; Y, Tanizawa; H, Watada; H, Suganami; S, Ishibashi

doi:10.1111/dom.13686

Public

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.

Shared by NobleBlocks on Apr 1, 2019 • 12:00 AM UTC

Authors:

Araki E

Yamashita S

Arai H

Abstract

The aim of this study was to evaluate the efficacy and safety of pemafibrate in people with type 2 diabetes and hypertriglyceridaemia over a 52-week period. Participants were randomly assigned to receive treatment with placebo or pemafibrate at a dose of 0.2 or 0.4 mg/d for 24 weeks (treatment perio...

Subject

Type 2 diabetes

Dyslipidaemia

Clinical Trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!